TrialBMC cancer2018

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

Francesca Battaglin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.